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nd/4.0/).One of the limitations in the current practice of brachytherapy
is that the cumulative, sub-volume doses of organs at risk (OARs)
over the course of fractionated treatment are difficult to be
assessed. The specific doses for OARs are often derived by simply
adding the dose–volume histogram (DVH) parameters of the whole
organ without spatial consideration; therefore, the number of
high-dose-rate brachytherapy (HDRBT) fractions may amplify the
dosimetric uncertainties of OARs [1–4]. Evaluation of interfraction
organ deformation and its association with dose distribution are
essential to analyze the risk of acute and late adverse events on
OARs [5].
To quantify the topographic and dosimetric changes during
multiple brachytherapy fractions, we adapted a surface-based
non-rigid registration on the basis of a Gaussian mixture model
(GMM) [6] to document the changing patient anatomy. Owing to
its higher accuracy and feasibility, compared with an intensity-
based algorithm, the surface-based deformable registration
approach has been employed in handling organs with large defor-
mations [7,8]. Using a similar methodology, Andersen et al. [9] per-
formed a significant study to evaluate three-dimensional (3D) dose
distribution after two fractions of pulse-dose-rate brachytherapy
for uterine cervical cancer. However, the difficulty lays in modelinga common reference frame for registration of multiple structures in
HDRBT, which generally needs 3–5 fractions [10].
To identify dosimetric variations due to interfraction organ
deformation during four fractions of HDRBT, our present study pro-
posed a novel method that takes advantage of the residue surface
displacements determined by non-rigid registration to create a
patient-specific average organ structure. Using the average organ
structure as a reference frame, distribution-based addition of con-
secutive brachytherapy dose fractions was compared with simple
addition of DVH parameters.Materials and methods
Fifty patients with uterine cervical cancer who underwent four
fractions of HDRBT (24 Gy in 6-Gy fractions) after external beam
radiotherapy (EBRT) (median, 50 Gy in 2-Gy fractions) were
selected on the basis of the inclusion criteria (Appendix A). Details
regarding the treatment protocol are given in Appendix B.
After retrospectively reviewing the enrolled treatment plans,
one radiation oncologist (KK) repeated the delineation of the con-
tours of the bladder and rectum. The bladder was delineated by its
outer wall in all images where it was visible. The rectum was con-
toured from the level of the anus to the rectosigmoid flexure.
Organ volumes were calculated from the volume of the surface
mesh objects. Subsequently, a framework developed in-house that
used surface-based non-rigid registration was applied for each
556 Dosimetric variations in brachytherapypatient to create an average structure of all the four different
shapes of an organ in each HDRBT fraction. The description of
our image processing framework is provided in Appendix C; the
accuracy and consistency of our registration framework were val-
idated (Appendix D).
Finally, the dose grid from each fraction was mapped to the
average shape of the bladder and rectum (Fig. 1). Because
Wachter-Gerstner et al. reported that small volumes less than
2 cm3 were mainly situated within the organ wall [11], we esti-
mated the distribution-based DVH parameters on the basis of the
area of the organ surface. The cumulative dose differences (simple
DVH parameter addition minus distribution-based dose addition)
of D2cm3 and D0:1cm3 between simple DVH parameter addition and
distribution-based dose addition were calculated for each consec-
utive fraction of HDRBT. For example, to calculate the cumulative
dose difference of D2cm1 for three consecutive fractions, the sum
of D2cm3 from the first to the third fractions was subtracted from
the D2cm3 of the reference frame, on which dose distributions from
the first to the third fractions were spatially accumulated. For
expressing the equivalent dose in 2 Gy fractions (EQD2) in HDRBT,
the a/b of a linear quadratic model was assumed as 3 Gy for OARs
[12].
Data were presented as mean ± standard deviation, unless
otherwise specified. Statistical analysis was performed using JMP
version 10.0 (SAS Institute, Cary, North Carolina). Wilcoxon signed
rank test was used to determine any difference between the two
groups. Statistical significance was set at a two-sided p-value of
<0.05.Results
With additional fractions of HDRBT, the cumulative dose differ-
ence showed a systematic tendency of the simple DVH parameter
addition to overestimate the dosimetric parameters, compared
with distribution-based dose addition, particularly in D0:1cm3Fig. 1. Representative organ surfaces from two patients show the interfraction variatio
HDRBT fractions were demonstrated on the basis of the average shape of the organs. HD(Fig. 2). A significant difference was also obtained for bladder
D2cm3 of more than two consecutive fractions. Linear regression
model showed that an additional HDRBT fraction was associated
with increases in the cumulative dose difference as follows:
0.3 ± 0.8 Gyab3 (2.8 ± 8.0% relative to the prescribed dose per frac-
tion as 10.8 Gyab3) for bladder D2cm3 (p = 0.005); 2.2 ± 1.6 Gyab3
(20.3 ± 14.9%) for bladder D0:1cm3 (p < 0.0001); 0.1 ± 0.4 Gyab3
(0.7 ± 3.4%) for rectum D2cm3 (p = 0.16); and 0.9 ± 0.7 Gyab3
(8.5 ± 6.6%) for rectum D0:1cm3 (p < 0.0001).
The average volume of the bladder was 216.5 ± 131.2 (range,
28.6–622.5) cm3, whereas that of the rectum was 52.5 ± 17.7
(range, 23.5–155.0) cm3. Because bladder volumes in our popula-
tion varied a lot, we investigated the effect of the magnitude of
bladder volume change on cumulative dose difference. Linear
regression model revealed that as the maximal range of bladder
volume difference increased by 100 cm3, the cumulative dose dif-
ference increased by 0.6 ± 1.6 Gyab3 (5.8 ± 14.8%) (p = 0.008) for
bladder D2cm3 and by 1.6 ± 3.7 Gyab3 (14.4 ± 34.5%) (p = 0.005) for
bladder D0:1cm3 . Furthermore, patients were divided into two
groups, according to the maximal range of bladder volume differ-
ence: controlled (<150 cm3) and uncontrolled (>150 cm3). For four
consecutive fractions, patients with controlled bladder volume
(n = 20) showed a significantly lower cumulative dose difference
of bladder D0:1cm3 , compared with patients with uncontrolled blad-
der volume (n = 30) [5.6 ± 3.8 Gyab3(51.7 ± 35.2%)
vs.7.9 ± 4.1 Gyab3(73.3 ± 37.9%), respectively; p = 0.04]. The two
groups did not show any significant difference for bladder D2cm3 .Discussion
We have presented here a novel framework of calculating the
dose difference due to organ motion and deformation, which con-
tribute to dosimetric variations during multi-fractionated HDRBT.
In the present study, because every applicator insertion was
imaged to obtain DVH parameters, the errors caused by simplen of spatial location of the D2cm3 region. The D2cm3 regions of the first to the fourth
RBT, high-dose-rate brachytherapy.
Fig. 2. Cumulative dose differences between simple DVH parameter addition and distribution-based dose addition, according to the consecutive fractions of HDRBT for
cervical cancer (A) The dose difference in bladder D2cm3 and bladder D0:1cm3 . (B) The dose difference in rectum D2cm3 and rectum D0:1cm3 .
*Significant difference.
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deformation.
Kirisits et al. discussed in a detailed literature review that the
largest dose uncertainties were related to inter- and intra-
fraction anatomical differences [13]. In the present study, an addi-
tional HDRBT fraction was significantly associated with increases
in cumulative dose difference of 2.8% for bladder D2cm3 20.3% for
bladder D0:1cm3 and 8.5% for rectum D0:1cm3 to the prescribed dose
per fraction. Andersen et al. previously reported that simple DVH
parameter addition overestimated bladder D2cm3 by 1.5% and blad-
der D0:1cm3 by 11% [9]. Dose difference of bladder D0:1cm3 showed
the higher value in our study and this may be because we did
not use a standard bladder filling protocol as recommended by
GEC-ESTRO [14]. Instead, we investigated the effect of the maximal
range of bladder volume difference on dosimetric variations. Con-
trolled bladder volumemay contribute to reduction of the dose dif-
ference by DVH parameter addition, particularly for D0:1cm3 , but the
effect on D2cm3 may be minimal.
Creating an average organ as a reference frame is necessary
when considering distribution-based dose addition with several
fractions of HDRBT. This is because deformable registration-
based dose addition depends on the choice of a reference frame
[9]. For example, when a larger bladder was transformed to a smal-
ler reference frame, the original 2 cm3 volume was likely to be
mapped to a smaller volume, resulting in an increased value of
D2cm3 and vice versa. In the present study, a possible explanation
for the significantly positive dose difference of bladder D2cm3 and
bladder D0:1cm3 for the first fraction in Fig. 2 may be the larger blad-
der volume of the first fraction, compared with those of the subse-
quent fractions.
Although recommendations from the gynecological GEC-ESTRO
working group assumed D2cm3 and D0:1cm3 to be contiguous [15],
some high dose regions were segregated (Fig. 1). Because high dose
regions can be non-contiguous owing to the shape of an organ wall,
we consider that these DVH parameters need not to be reported
from contiguous volumes.
There were several limitations in this study. Other possible
dosimetric uncertainties, such as organ contouring [16,17], intra-
fraction dose deviation [3,18], and applicator reconstruction [19],
were not taken into account. Also, there may be other possible ref-
erence frames, such as the anatomy used for developing the EBRT
plan. The results of this study were obtained from a particular
treatment schedule in our institution; therefore, the total effect
of interfraction organ deformation on the total delivered dose
may change in the other fractionation schedule of HDRBT. The clin-
ical relevance of distribution-based dose addition on morbidity formulti-fractionated HDRBT for cervical cancer patients needs to be
investigated further.
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